65,437 trials
Multiple Sclerosis
Primary: Overview of Adverse Events (AE] — 32; 35; 35; 3 participants
Diabetes Mellitus, Type 2
Primary: Hemoglobin A1c — -1.3; -0.4 HbA1c, %
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Trough FEV1 (L) at 28 Weeks on Treatment — 1.422; 1.356 Liters
Juvenile Idiopathic Arthritis
Primary: Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40) — 48.1; 25.6…
Sarcoma
Primary: Objective Response (Confirmed, Complete and Partial) — 1; 0; 1; 8 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Trough FEV1 (L) at 28 Weeks on Treatment — 1.220; 1.162 Liters
Lymphoma
Primary: Progression-free Survival — 90 percentage of participants
Bacteremia
Primary: Blood Culture Contamination — 41; 32; 25 blood culture sets
Bowel Preparation for Colonoscopy
Primary: The Overall Cleanliness of the Prep as Measured by the Ottawa Scale — 4.8; 6.2 Ottawa Score
Cancer
Primary: Part A: Area Under Plasma Concentration-time Curve (AUC) — 1920; 2392 ng*h/mL
Cardiovascular Risk Factors
Primary: Percent Change in Postprandial Glucose Levels — 6.34; -9.83 Percent change from baseline — p==0.033
Chronic Obstructive Pulmonary Disease
Primary: Change in Total Ventilation Volume — 0.154317; -0.13687 Litres
Sexual Dysfunction, Physiological
Primary: The Number of Patients Who Described Their Premature Ejaculation (PE) as At Least "Slightly Better" in Response to Dapoxetine Treatment — 228 Patients
Heartburn
Primary: Change in the Frequency of Heartburn During the 7-day Period Prior to the 8 Week Visit (Visit 3) Compared to the Frequency of Heartburn During the 7-day Period Prior to…
Hepatitis C · Hepatitis C, Chronic
Primary: Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility — 144; 77; 17; 7 participants